StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck organon Revenue — Europe and Canada ($M) ($M)

Organon & Co. Form 10-Q / 10-K

QuarterlyAnnual
Latest, FY2025
1,618,000,000
Period ended Dec 31, 2025
Change on a year earlier
-8.2%
1,763,000,000 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon Revenue — Europe and Canada ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,618,000,000-8.2%Organon & Co. SEC Filing (0001628280-26-011125) ↗
FY2024Dec 31, 20241,763,000,000+5.4%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2023Dec 31, 20231,673,000,000+2.6%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2022Dec 31, 20221,631,000,000-6.3%Organon & Co. SEC Filing (0001821825-25-000006) ↗
FY2021Dec 31, 20211,741,000,000+0.9%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2020Dec 31, 20201,726,000,000-8.8%Organon & Co. SEC Filing (0001821825-23-000003) ↗
FY2019Dec 31, 20191,893,000,000–Organon & Co. SEC Filing (0001821825-22-000002) ↗

Cite this data

StockData. (2026). Merck Organon Revenue — Europe and Canada ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_geo_eu_ca

See every metric in the Merck KPI table. Data updated Oct 26, 2026.